FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:2173-2174 December 26, 2002 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Antifungal azoles with activity against aspergillus include itraconazole and three new drugs: voriconazole, posaconazole, and ravuconazole. Voriconazole was recently approved for the treatment of invasive mold infections, and posaconazole and ravuconazole are undergoing clinical evaluation. Resistance of Aspergillus fumigatus against itraconazole has been documented, and a degree of cross-resistance between itraconazole and posaconazole and between voriconazole and ravuconazole has been suggested on the basis of similarities in molecule structure.¹ We describe a patient in whom invasive aspergillosis developed as a result of infection with an A. fumigatus strain for which the minimal inhibitory concentrations (MICs) of all . . . [Full Text of this Article]

This article has been cited by other articles:

• Arendrup, M. C., Perkhofer, S., Howard, S. J., Garcia-Effron, G., Vishukumar, A., Perlin, D., Lass-Florl, C. (2008). Establishing In Vitro-In Vivo Correlations for Aspergillus fumigatus: the Challenge of Azoles versus Echinocandins. Antimicrob. Agents Chemother. 52: 3504-3511 [Abstract] [Full Text]  
• Cowen, L. E., Steinbach, W. J. (2008). Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance. Eukaryot Cell 7: 747-764 [Full Text]  
• Verweij, P. E., Mellado, E., Melchers, W. J.G. (2007). Multiple-Triazole-Resistant Aspergillosis. NEJM 356: 1481-1483 [Full Text]  
• Antachopoulos, C., Meletiadis, J., Sein, T., Roilides, E., Walsh, T. J. (2007). Use of high inoculum for early metabolic signalling and rapid susceptibility testing of Aspergillus species. J Antimicrob Chemother 59: 230-237 [Abstract] [Full Text]  
• Dannaoui, E., Garcia-Hermoso, D., Naccache, J. M., Meneau, I., Sanglard, D., Bouges-Michel, C., Valeyre, D., Lortholary, O. (2006). Use of voriconazole in a patient with aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus.. J Med Microbiol 55: 1457-1459 [Abstract] [Full Text]  
• MacCallum, D. M., Whyte, J. A., Odds, F. C. (2005). Efficacy of Caspofungin and Voriconazole Combinations in Experimental Aspergillosis. Antimicrob. Agents Chemother. 49: 3697-3701 [Abstract] [Full Text]  
• Xiong, Q., Hassan, S. A., Wilson, W. K., Han, X. Y., May, G. S., Tarrand, J. J., Matsuda, S. P. T. (2005). Cholesterol Import by Aspergillus fumigatus and Its Influence on Antifungal Potency of Sterol Biosynthesis Inhibitors. Antimicrob. Agents Chemother. 49: 518-524 [Abstract] [Full Text]  
• Te Dorsthorst, D. T. A., Verweij, P. E., Meis, J. F. G. M., Punt, N. C., Mouton, J. W. (2004). In Vitro Interactions between Amphotericin B, Itraconazole, and Flucytosine against 21 Clinical Aspergillus Isolates Determined by Two Drug Interaction Models. Antimicrob. Agents Chemother. 48: 2007-2013 [Abstract] [Full Text]  
• Balajee, S. A., Weaver, M., Imhof, A., Gribskov, J., Marr, K. A. (2004). Aspergillus fumigatus Variant with Decreased Susceptibility to Multiple Antifungals. Antimicrob. Agents Chemother. 48: 1197-1203 [Abstract] [Full Text]  
• van't Wout, J. W., van Dissel, J. T. (2004). Fungal infection in hemato-oncologic patients: better to prevent than to treat?. Blood 103: 1182-1183 [Full Text]  
• Andrews, T., Sullivan, K. E. (2003). Infections in Patients with Inherited Defects in Phagocytic Function. Clin. Microbiol. Rev. 16: 597-621 [Abstract] [Full Text]  
• Berger, V. W., Franzblau, M. J., Verweij, P. E., Warris, A., Weemaes, C. M., Gallin, J. I., Wesley, R., Holland, S. M. (2003). Preventing Fungal Infections in Chronic Granulomatous Disease. NEJM 349: 1190-1191 [Full Text]